Sunday, July 15, 2018
Company News: Page (1) of 1 - 04/16/18 Email this story to a friend. email article Print this page (Article printing at page facebook
Preclinical Data Presented at AACR 2018 Shows Esperance Pharmaceuticals' EP-100 Is Synergistic with PARP Inhibitor Olaparib in Ovarian Cancer
Studies Conducted by MD Anderson Cancer Center Elucidate the Mechanisms by Which EP-100 Kills Ovarian Cancer Cells on Its Own and Synergistically in Combination with a Leading PARP Inhibitor
(April 16, 2018)
This article is no longer available,but here are some related topics.

Page: 1

Related Keywords: Inc.,Science,Lifestyle,Medical,Biology,Genetics,Cancer,Other,
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter

Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines